PRIMARY STUDY

A systematic review of the antipsychotic properties of cannabidiol in humans

Key Findings:  Cannabidiol (CBD), a non-psychotropic component of cannabis, exhibits potential antipsychotic properties beneficial for treating schizophrenia by counteracting the psychotic symptoms and cognitive impairments associated with cannabis use and acute Δ9-tetrahydrocannabinol (THC) exposure, potentially through modulating brain activity in key areas like the striatum, hippocampus, and prefrontal cortex, as supported by initial clinical studies suggesting its safety and efficacy, although larger trials are necessary for clinical validation.